The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018

Paolo A. Ascierto, Paolo Bruzzi, Alexander Eggermont, Omid Hamid, Hussein A. Tawbi, Alexander Van Akkooi, Alessandro Testori, Corrado Caracò, Igor Puzanov, Francesco Perrone

Research output: Contribution to journalArticle

Abstract

The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.

Original languageEnglish
Article number148
JournalJournal of Translational Medicine
Volume17
Issue number1
DOIs
Publication statusPublished - May 10 2019

Fingerprint

CTLA-4 Antigen
Melanoma
Ligands
Pharmaceutical Preparations
Neoadjuvant Therapy
Italy
Clinical Trials
Survival

Keywords

  • Adjuvant
  • Anti-CTLA-4
  • Anti-PD-1
  • BRAF inhibitor
  • Immunotherapy
  • MEK inhibitor
  • Melanoma
  • Neoadjuvant
  • Targeted therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018. / Ascierto, Paolo A.; Bruzzi, Paolo; Eggermont, Alexander; Hamid, Omid; Tawbi, Hussein A.; Van Akkooi, Alexander; Testori, Alessandro; Caracò, Corrado; Puzanov, Igor; Perrone, Francesco.

In: Journal of Translational Medicine, Vol. 17, No. 1, 148, 10.05.2019.

Research output: Contribution to journalArticle

Ascierto, Paolo A. ; Bruzzi, Paolo ; Eggermont, Alexander ; Hamid, Omid ; Tawbi, Hussein A. ; Van Akkooi, Alexander ; Testori, Alessandro ; Caracò, Corrado ; Puzanov, Igor ; Perrone, Francesco. / The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018. In: Journal of Translational Medicine. 2019 ; Vol. 17, No. 1.
@article{5d8a50f5e464469c8008c96e796d090d,
title = "The great debate at {"}melanoma Bridge 2018{"}, Naples, December 1st, 2018",
abstract = "The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.",
keywords = "Adjuvant, Anti-CTLA-4, Anti-PD-1, BRAF inhibitor, Immunotherapy, MEK inhibitor, Melanoma, Neoadjuvant, Targeted therapy",
author = "Ascierto, {Paolo A.} and Paolo Bruzzi and Alexander Eggermont and Omid Hamid and Tawbi, {Hussein A.} and {Van Akkooi}, Alexander and Alessandro Testori and Corrado Carac{\`o} and Igor Puzanov and Francesco Perrone",
year = "2019",
month = "5",
day = "10",
doi = "10.1186/s12967-019-1892-5",
language = "English",
volume = "17",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018

AU - Ascierto, Paolo A.

AU - Bruzzi, Paolo

AU - Eggermont, Alexander

AU - Hamid, Omid

AU - Tawbi, Hussein A.

AU - Van Akkooi, Alexander

AU - Testori, Alessandro

AU - Caracò, Corrado

AU - Puzanov, Igor

AU - Perrone, Francesco

PY - 2019/5/10

Y1 - 2019/5/10

N2 - The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.

AB - The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.

KW - Adjuvant

KW - Anti-CTLA-4

KW - Anti-PD-1

KW - BRAF inhibitor

KW - Immunotherapy

KW - MEK inhibitor

KW - Melanoma

KW - Neoadjuvant

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85065589434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065589434&partnerID=8YFLogxK

U2 - 10.1186/s12967-019-1892-5

DO - 10.1186/s12967-019-1892-5

M3 - Article

AN - SCOPUS:85065589434

VL - 17

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 148

ER -